Innovent Biologics grants share options and restricted shares to employees, director

Innovent Biologics, Inc. granted 20,800 share options to five grantees and 212,300 restricted shares to 19 grantees on August 29, 2025. Among these grants, Dr. Sherwin, an independent non-executive director, received 1,800 options and 5,100 restricted shares. The exercise price for the options is HK$96.85 per Share.

The options granted to non-connected employees will vest 75% on August 29, 2028, and 25% on August 29, 2029, contingent on individual annual performance targets. Dr. Sherwin's options and restricted shares will vest in three equal tranches (33.33%) on August 29, 2026, 2027, and 2028, respectively, without performance targets.

The market value of the restricted shares granted totals approximately HK$20,561,255, based on the closing price of HK$96.85 per Share on the grant date. These grants aim to incentivize, retain, and reward eligible participants, aligning their interests with the company's long-term growth and shareholder value.